Jacksonville, FL., December 18, 2023 – OrthoSpineNews – Theragen, a medical technology company, today announced the company’s issuance of two new U.S. patents and the allowance of its pending U.S. patent application. Together with two previously issued patents (U.S. 11,395,919 and 11,426), this further demonstrates Theragen’s contribution to innovation in the field of post-surgical therapeutics, patient engagement, and digital data insights.
Richard Pearce COO and VP of R&D says, “These patents provide protection for the unique, differentiating elements of Theragen’s ActaStim® bone growth stimulator system, which is intentionally designed to improve patient compliance and spinal fusion success.”
U.S. Patent 11,717,685, which was issued on August 8, 2023, focuses on tracking the intensity level of patient activity together with device usage, comparing this data against the prescribed therapy regimen to deliver insight into the recovery process for patients and surgeons. 
U.S. Patent 11,759,637, which was issued on September 19, 2023, correlates system usage with the patient’s physiology to ensure patient confidence in the ongoing treatment and encourage patient compliance with the therapy regimen.
U.S. Patent Application Publication No. 2022/0387783, which was allowed on August 30, 2023, will be issued later this year with claims of comparing patient physiological data with patient-reported outcome measures, such as post-operative pain level, and to optimize the therapy regimen using this data.
Chris McAuliffe CEO and President says, “The issuance of five patents in just over two years, reflects our ongoing commitment innovation in the field of IoT and data-driven insight generation. Our belief is that capturing, combining, and graphically displaying key recovery metrics enables patients to play an active role in their healing journey and provides Healthcare Providers a comprehensive and accurate picture of their patient’s recovery progress.”
About Theragen:
Theragen, Inc. is a leader in the development and manufacture of non-invasive, electrical stimulation DME products that deliver therapeutic energy to improve fusion success and empower patients to play an active role in their recovery. The company is committed to continuous innovation and expanding our reach to help improve outcomes for more patients. To learn more, please visit theragen.com.
About ActaStim® Bone Growth Stimulator System:
ActaStim uses safe, effective, FDA-approved stimulation technology that’s been prescribed clinically for over 20 years to improve spinal fusion success and help patients get back to the activities they enjoy.[1]
SOURCE: Theragen
[1]U.S. Food and Drug Administration. (2020). PMA P190030: FDA Summary of Safety and Effectiveness Data.
